Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial

References

• HarrisMIFlegalKMCowieCCPrevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988–1994Diabetes Care19982145185249571335
   PubMed Web of Science ®Google Scholar
• NelsonREverhartJKnowlerWBennettPIncidence, prevalence and risk factors for non-insulin-dependent diabetes mellitusPrim Care19881522272503290917
   PubMed Web of Science ®Google Scholar
• KatonWLinEHKroenkeKThe association of depression and anxiety with medical symptom burden in patients with chronic medical illnessGen Hosp Psychiatry200729214715517336664
   PubMed Web of Science ®Google Scholar
• GoldenSHLazoMCarnethonMExamining a bidirectional association between depressive symptoms and diabetesJAMA2008299232751275918560002
   PubMed Web of Science ®Google Scholar
• KatonWJThe comorbidity of diabetes mellitus and depressionAm J Med200812111S8S1518954592
   PubMed Web of Science ®Google Scholar
• EiberRBerlinIGrimaldiABisserbeJInsulin-dependent diabetes and psychiatric pathology: general clinical and epidemiologic reviewL’Encephale1996235351357
   Web of Science ®Google Scholar
• GeffkenGRWardHEStaabJPCarmichaelSLEvansDLPsychiatric morbidity in endocrine disordersPsychiatr Clin N Am1998212473489
   PubMed Web of Science ®Google Scholar
• BrownESVargheseFPMcEwenBSAssociation of depression with medical illness: does cortisol play a role?Biol Psychiatry20045511914706419
   PubMed Web of Science ®Google Scholar
• LustmanPJGriffithLSFreedlandKEClouseREThe course of major depression in diabetesGen Hosp Psychiatry19971921381439097068
   PubMed Web of Science ®Google Scholar
• LustmanPJGriffithLSClouseREEffects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trialPsychosom Med19975932412509178335
   PubMed Web of Science ®Google Scholar
• VamosEPMucsiIKeszeiAKoppMSNovakMComorbid depression is associated with increased healthcare utilization and lost productivity in persons with diabetes: a large nationally representative Hungarian population surveyPsychosom Med200971550150719528291
   PubMed Web of Science ®Google Scholar
• ChenJ-JLiuZFanS-HCombined application of NMR-and GC-MS-based metabonomics yields a superior urinary biomarker panel for bipolar disorderScientific Rep201445855
   PubMed Web of Science ®Google Scholar
• ChenJ-JHuangHZhaoL-BSex-specific urinary biomarkers for diagnosing bipolar disorderPloS One2014912e11522125531985
   PubMed Web of Science ®Google Scholar
• YangJChenTSunLPotential metabolite markers of schizophreniaMol Psychiatry2013181677822024767
   PubMed Web of Science ®Google Scholar
• O’KaneMWilesPWalesJFluoxetine in the treatment of obese type 2 diabetic patientsDiabet Med19941111051108181239
   PubMed Web of Science ®Google Scholar
• GrayDFujiokaKDevineWBrayGA randomized double-blind clinical trial of fluoxetine in obese diabeticsInt J Obes Relat Metab Disord: J Int Assoc Study Obes199216S67S72
   PubMed Web of Science ®Google Scholar
• LevineLEnasGThompsonWUse of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study (with a commentary by Michael Weintraub)Int J Obes19881356356452583918
   PubMed Web of Science ®Google Scholar
• GülserenLGülserenSHekimsoyZMeteLComparison of fluoxetine and paroxetine in type II diabetes mellitus patientsArch Med Res200536215916515847950
   PubMed Web of Science ®Google Scholar
• Paile-HyvarinenMWahlbeckKErikssonJGQuality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trialBMC Fam Pract20034712747810
   PubMedGoogle Scholar
• KaraiskosDTzavellasEIliasILiappasIPaparrigopoulosTAgomelatine and sertraline for the treatment of depression in type 2 diabetes mellitusInt J Clin Pract201367325726023409693
   PubMed Web of Science ®Google Scholar
• CronkBCHow to Use SPSSA Step-by-Step Guide to Analysis and InterpretationGlendale, CAPyrczak Pub2004
   Google Scholar
• MillerGAChapmanJPMisunderstanding analysis of covarianceJ Abnorm Psychol200111014011261398
   PubMed Web of Science ®Google Scholar
• GoodnickPJKumarAHenryJHBukiVGoldbergRBSertraline in coexisting major depression and diabetes mellitusPsychopharmacol Bull19963322612649230640
   PubMedGoogle Scholar
• LustmanPJFreedlandKEGriffithLSClouseRFluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trialDiabet Care2000235618623
   PubMed Web of Science ®Google Scholar
• Paile-HyvärinenMWahlbeckKErikssonJGQuality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trialBMC Fam Pract200341712747810
   PubMedGoogle Scholar
• TamuraYTanakaYSatoFEffects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patientsJ Clin Endocrin Metabol200590631913196
   PubMed Web of Science ®Google Scholar
• KohenDBurgessACatalanJLantAThe role of anxiety and depression in quality of life and symptom reporting in people with diabetes mellitusQual Life Res1998731972049584549
   PubMed Web of Science ®Google Scholar
• PetrakFHerpertzSTreatment of depression in diabetes: an updateCurr Opin Psychiatry200922221121719553878
   PubMed Web of Science ®Google Scholar
• PlesničarBKEfficacy and tolerability of agomelatine in the treatment of depressionPat Prefer Adher20148603
   PubMed Web of Science ®Google Scholar
• GahrMAgomelatine in the treatment of major depressive disorder: an assessment of benefits and risksCurr Neuropharmacol2014125387398
   Web of Science ®Google Scholar
• IvanovSVSamushiyaMAAgomelatine in the treatment of depressive disorders in clinical practice: multicenter observational CHRONOS studyNeuropsychiatr Dis Treat20141063124790445
   PubMed Web of Science ®Google Scholar